Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10345)	2/8/2004 5:50:45 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

>> I'm blanking right now on actual examples << RGEN and autism. >> So sometimes it's self-deception as much as any attempt at deliberate deception << >> my sense is that the average quality of biotech pipeline has improved over the last five years - lower proportion of bait and switch projects << Big-time improvement. The sector has a much higher percentage of legitimate efforts.

To: Biomaven who wrote (10345)	2/8/2004 6:13:30 PM
From: software salesperson	Respond to of 52153

peter, It's interesting to look at biotech companies founded by someone who has a personal stake in the disease (typically an afflicted family member). another example is cell pathways, acquired by osip. The company, based in Horsham, Pa., had spent 11 years developing this treatment for an inherited precancerous disorder, familial adenomatous polyposis (FAP). Cell Pathways' story is laden with an extra burden of emotion--the company was co-founded by Pamukcu and one of his patients, Floyd Nichols. Nichols suffered from FAP, a genetic disease that produces hundreds of precancerous polyps in the colon. The polyps can be removed, but they keep returning, often necessitating removal of the colon. Nichols had his removed at age 19, but polyps began showing up in his intestines in his mid-30s. Rather than have parts of his small intestine and stomach removed, Nichols, a computer salesman, searched for an alternative. That led him to Dr. William Waddell, a now retired surgeon at the University of Colorado Health Sciences Center. Waddell had anecdotal evidence that polyps in FAP patients could be melted away with sulindac, a 20-year-old arthritis drug from Merck that was just coming off patent. Nichols persuaded Pamukcu, his doctor at the University of Chicago, to treat him with the drug--and it worked. Doctor and patient were so elated they joined forces to found Cell Pathways in 1989 to commercialize their discovery. By now Nichols had a second crucial reason to find a cure: His son, Eric, born in 1988, also had FAP. businessweek.com sales

To: Biomaven who wrote (10345)	2/9/2004 9:29:07 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

>> I'm blanking right now on actual examples << I forgot.... one of the best..... legalbrief.co.za Anyone read it???? I was V.P. Product Development at BD Pharmingen (then just PharMingen) when the "Baxter" letters went out. It was my job to look at claims and determine their validity and the degree, if any, to which we were infringing them. I considered the claims to be bullet-proof, and could not conceive of why CellPro was challenging. As Murdoch and Kiley were driving CellPro into the ground, Richard Miller (a CellPro founder who bragged about such, until it was no longer a bragging issue) was appointing Kiley to the PCYC Board.